The use of receiver operating characteristic analysis for detection of minimal residual disease using five-color multiparameter flow cytometry in acute myeloid leukemia identifies patients with high risk of relapse

Cytometry. Part B, Clinical Cytometry
Adhra Al-MawaliIan Lewis

Abstract

Multiparameter flow cytometry (MFC) has been shown to be a useful approach for detection of minimal residual disease (MRD). The aim of the study was to determine the optimal threshold that can separate patients into two groups in terms of leukemic residual cells and relapse status after induction and consolidation chemotherapy. Five-color MFC and receiver operating characteristics (ROC) analysis were used to determine the optimal threshold. This study analyzed 54 acute myeloid leukemia (AML) patients. LAPs were detected in 51/54 (94%) patients. MRD was evaluated in the bone marrow (BM) in morphologic complete remission from 25 and 22 patients after induction and consolidation, respectively. The threshold discriminating MRD(-) from MRD(+) cases was set at 0.15% residual leukemic cells, a level that allowed optimal sensitivity and specificity for prediction of relapse, both at postinduction (P = 0.05) and postconsolidation (P = 0.009) time points using ROC analysis. MRD level postinduction not only influenced relapse-free survival (RFS) (P = 0.004) but also overall survival (OS) (P = 0.003). Multivariate analysis showed that MRD level postinduction was a powerful independent prognostic factor for both RFS (P = 0.037) and OS (P = ...Continue Reading

References

Oct 16, 1996·Journal of the National Cancer Institute·E L SieversM R Loken
Dec 16, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J CiudadA Orfao
Sep 30, 1999·The New England Journal of Medicine·B LöwenbergA Burnett
Nov 5, 1999·The New England Journal of Medicine
May 2, 2002·Journal of Hematotherapy & Stem Cell Research·Adriano VendittiSergio Amadori
May 25, 2002·British Journal of Haematology·Dorine BrestersGertjan J L Kaspers
Oct 9, 2003·British Journal of Haematology·Elaine Coustan-SmithDario Campana
Nov 1, 2003·Best Practice & Research. Clinical Haematology·María B VidrialesDario Campana
Dec 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards
Jun 5, 2004·Acta Haematologica·P Raanani, I Ben-Bassat
Sep 28, 2004·The Hematology Journal : the Official Journal of the European Haematology Association·Wolfgang KernTorsten Haferlach

❮ Previous
Next ❯

Citations

Aug 12, 2009·Current Opinion in Oncology·Francesco BuccisanoAdriano Venditti
Nov 30, 2010·Best Practice & Research. Clinical Haematology·Wolfgang KernTorsten Haferlach
Sep 26, 2009·Clinical Lymphoma & Myeloma·David ShookDario Campana
Dec 17, 2011·Cytometry. Part B, Clinical Cytometry·Hanne Ø LarsenPeter Hokland
Mar 10, 2011·British Journal of Haematology·Gert J OssenkoppeleGerrit Jan Schuurhuis
Oct 24, 2013·Cytometry. Part B, Clinical Cytometry·W ZeijlemakerG J Schuurhuis
Jun 26, 2012·The International Journal of Biochemistry & Cell Biology·Kaustubh N BhingeYong-Yu Liu
Dec 20, 2008·American Journal of Clinical Pathology·Adhra Al-MawaliIan Lewis
Jul 11, 2013·Cytometry. Part a : the Journal of the International Society for Analytical Cytology·Adhra Al-MawaliIbrahim Al-Zakwani
Jul 29, 2016·Journal of Hematology & Oncology·Adhra Al-MawaliIan Lewis
Nov 18, 2018·Current Hematologic Malignancy Reports·Franklin Fuda, Weina Chen
Jul 27, 2021·Clinics in Laboratory Medicine·Xueyan Chen, Sindhu Cherian

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.